Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Roles of Uremic Toxins in Uremic Sacropenia

10 mars 2020 mis à jour par: Tungs' Taichung Metroharbour Hospital

Association of Uremic Toxins and Sacropenia in Hemodialysis Patients

Background. In advanced chronic kidney disease (CKD), multiple metabolic and nutritional abnormalities may contribute to the impairment of skeletal muscle mass and function thus predisposing patients to the condition of sarcopenia. Herein, we aim to investigate the association of uremic toxins and sacropenia. In addition, the prevalence and mortality predictive power of sarcopenia, defined by different methods, in a cohort of hemodialysis patients.

Methods. We plan to evaluate 300 HD patients. Sarcopenia was defined as reduced muscle function assessed by handgrip strength (HGS <30th percentile of a population-based reference adjusted for sex and age) plus diminished muscle mass assessed by different methods: (i) midarm muscle circumference (MAMC) <90% of reference value (A), (ii) muscle wasting by DEXA (B) and (iii) reduced skeletal muscle mass index (<10.76 kg/m² men; <6.76 kg/m² women) estimated by bioelectrical impedance analysis (BIA) (C). Serum levels of 3 established uremic toxins such as indoxyl sulfate, p-cresol and hippuric acid will be measured. Besides, various relevant inflammatory markers will also be assessed. Patients will be followed for up to 3 years for all-cause mortality.

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

Patients and Methods

This study will included 300 consecutive patients receiving maintenance hemodialysis at the outpatient dialysis center of the Tungs Taichung Metroharbour Hospital, Taichung Taiwan. Recruitment will start after approval of the Ethics Committee of our hospital. Exclusion criteria were age of <20 and >90 years, clinical signs of acute infection during the month preceding the inclusion, active cancer or liver disease at the time of evaluation, previous diagnosis of immunological diseases and unwillingness to participate in the study. Physician will perform a complete chart review and interviewed each patient regarding their clinical history.

All MHD patients enrolled in our study will be tested with DEXA and bioelectrical impedance analysis (BIA) and grip strength. Demographic data was collected and anthropometric measurement such as mid-arm muscle circumference (MAMC) calf circumference, and laboratory examination are conducted.

Handgrip strength

Muscle strength is assessed in the dominant hand using a Jamar hand dynamometer (Lafayette Instrument Company, USA). Patients are first familiarized with the device and were then examined standing with both arms extended sideways from the body with the dynamometer facing away from the body. Patients were instructed to grip the dynamometer with the maximum strength in response to a voice command, and the highest value of three measurements was considered for the study. Handgrip strength (HGS) values under the 30th percentile from a specific-population reference value adjusted for age and sex were considered as reduced.

Anthropometry

Body mass index (BMI) is calculated as weight in kilograms divided by height in squared meters. MAMC is calculated according to the following equation, based on mid-arm circumference (measured at mid-point from the acromion to olecranon) and the triceps skinfold (using caliper Lange®, Cambridge Scientific Industries, Inc.).

Values of MAMC were compared with the 50th percentile of NHANES II and standard adequacy of <90% was considered as reduced muscle mass .

Bioelectrical impedance analysis

Body composition was measured using an 8-contact electrode bioelectrical impedance analysis (BIA) device (Tanita BC-418, Tanita, Tokyo, Japan), and followed the standard procedure and the manufacturer's instructions. This BIA device was used to measure the whole body and segmental impedance (± 1Ω) at a frequency of 50 kHz, and it provided valid muscle mass estimates (kg) of each of the four extremities.[2 Appendicular muscle mass (ASM) was calculated as the sum of the estimated muscle mass for the arms and legs. A relative skeletal muscle mass index (ASM/ht2) normalized for height was defined as the ratio of ASM (kg) and the height squared(m2). For this analysis, we defined muscle mass cut-off points according to the distribution of ASM/ht2 of a young population comprising 998 healthy adults (aged 20-40 years) or the study population. A participant was considered to have low muscle mass if his or her ASM/ht2 was below -2 standard deviations of the reference young adult values defined in previous studies (6.76 kg/m2 for men and 5.28 kg/m2 for women).

Sarcopenia diagnosis

The diagnosis of sarcopenia was based on the presence of derangements in both muscle function and muscle mass. For the purpose of the study, we considered one muscle function indicator (reduced HGS) associated with one of three indicators of muscle mass (MAMC, DEXA or BIA). Therefore, reduced HGS in association with an MAMC of <90% of the standard adequacy (Method A), presence of muscle wasting by DEXA (MethodB) or reduced SMMI by BIA(MethodC) were considered as diagnosis of sarcopenia.

Laboratorial parameters

All blood samples are collected during the midweek dialysis from the AV fistula, immediately after the insertion of the dialysis cannula but before the administration of heparin. Blood is sampled in 4 c.c. Venoject II tubes, centrifuged (10 min, 3000 rpm) and immediately store at -70°C until assayed. Serum albumin, urea, creatinine, and total protein concentrations in serum are determined according to standard methods. The serum levels of hsCRP are measured using a Behring Nephelometer II (Dade Behring, Tokyo, Japan). Serum concentrations of total p-cresol sulfate, hippuric acid and IS (i.e., combined free and protein bound fractions) are analyzed with High-performance liquid chromatography (HPLC). Briefly, for binding competition, 200μl serum to which we added 20μl 0.50mM 1-naphthalenesulfonic acid (internal standard) was vortex-mixed with 250μl 0.24M sodium octanoate (binding competitor).After incubation at room temperature for 5min, we added 2ml cold acetone to precipitate proteins. Following vortex-mixing and centrifuging at 4 ◦C, 1860×g for 20 min, the supernatant was transferred to 12mm×100mm, GL 14 glass test tubes and 2ml dichloromethane was added. After vortex-mixing and centrifuging at 4 ◦C, 1860×g for 10min, 200μl of the upper layer was transferred to glass autosampler vials, followed by addition of 20μl 1M HCl and 15μl was injected onto the HPLC. The HPLC analysis was performed on an Agilent 1100 series LC (Santa Clara, CA),and Agilent ChemStations software were used for the chromatographic analysis. The separation was carried out on a ZORBAX SB-C18 Solv Saver Plus HPLC column (5 μm, 3.0 mm×150 mm).at a flow rate of 0.6 ml/min. Mobile phase A is 0.2% trifluoroacetic acid in Milli-Q water and mobile phase B is 0.2% trifluoroacetic acid in acetonitrile. The analytical method consists of an isocratic run with 92% mobile phase A for 23 min.. Each analytical run was followed by a 1.3 min washout gradient to 100% B. Column temperature was 25 ◦C, and autosampler tray temperature was 6 ◦C. We quantified the analytes by using the analyte to standard peak area ratio on a Agilent 1100 High Performance Fluorescence detector G1321A and Agilent 1100 Series UV-Visible detectors G1314A. Detector settings were λex 260 nm/λem288nm for p-cresyl sulfate and λex 280 nm/λem 390nm for indoxyl sulfate and internal standard. Hippuric acid was monitored by UV-Vis detector at 254 nm. Quantitative results are obtained and calculated in terms of their concentrations (mg/L).

Blood samples are also collected before dialysis for measurement of oxidative stress (CML, Nε-(carboxymethyl)lysine ) and inflammatory markers (IL-6). Serum Nε-(carboxymethyl)lysine (CML) was determined using enzyme-linked immunosorbent assay (R&D system, Minneapolis, MN, USA). Similarly, the concentration of IL-6 is also assessed using Quantikine Human Interleukin Immunoassay (R&D Systems Minneapolis, MN, USA) with a detection limit of 15 pg/L and 0.12 pg/mL, respectively. In addition, serum irisin, urotensin II, follistatin and alpha 1 antichymotrypsin concentrations are measured by using the human enzyme-linked immunosorbent assay (ELISA) kits in accordance with the manufacturer's instructions. The All determinations are performed in duplicate, and the mean value is used.

Statistical analyses

The variables are expressed in mean±SD, median (interquartile range) or proportions. Variable distributions are tested by e.g. Shapiro Wilk test, and those not normally distributed are standardized by using z-score.Studentt-test or Chi-square test is employed for the comparisons between sarcopenic and non-sarcopenic patients. Kappa test is used to evaluate the agreement among the methods. Survival analyses are made with the Kaplan-Meier survival curve and the Cox proportional hazard model. The univariate and multivariate Cox-regression analyses are presented as hazard ratio [HR; 95% confidence intervals (CI)]. Statistical significance is set at the level of P<0.05, and the analyses are performed by using the SPSS software version 18 (SPSS, Inc., Chicago, IL, USA)

Type d'étude

Observationnel

Inscription (Réel)

111

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Taichung, Taïwan
        • Tungs' Taichung MetroHarbour Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

20 ans à 90 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

hemodialysis (HD) patients

La description

Inclusion Criteria:

  • Both sexes aged between 20-90 years. Received stable hemodialysis at least 3 months. Written informed consent.

Exclusion Criteria:

  • clinical signs of acute infection during the month preceding the inclusion, active cancer or liver disease at the time of evaluation, previous diagnosis of immunological diseases and unwillingness to participate in the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Presence of Sarcopenia
Délai: 3 years
To evaluate the association of sacropenia defined according to 1. Low muscle mass 2. Low muscle strength 3. Low physical performance and serum levels of some uremic toxins such as indoxyl sulfate, p-cresol and hippuric acid will be measured.
3 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 avril 2017

Achèvement primaire (Réel)

31 décembre 2018

Achèvement de l'étude (Réel)

31 janvier 2020

Dates d'inscription aux études

Première soumission

17 février 2017

Première soumission répondant aux critères de contrôle qualité

17 février 2017

Première publication (Réel)

23 février 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

11 mars 2020

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 mars 2020

Dernière vérification

1 mars 2020

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

3
S'abonner